drugset / Trial / NCT00526071
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
NaSingle-groupOpen-labelTreatment
Summary
Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
Timeline
- Start
- 2007-09-17
- Primary completion
- 2012-09-08
- Completion
- 2012-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | migalastat | Other / unclassified | 150 mg | Oral |